Form 4: Zentalis Pharmaceuticals Executive Receives Stock Grant
Insider Transaction (Form 4)
Ingmar Bruns, Chief Medical Officer of Zentalis Pharmaceuticals, Inc., received 9,727 shares of common stock on September 30, 2026.
Summary
- Grant/award: acquired 9,727 Common Stock at $2.18 ($21,205) on September 30, 2026; holds 43,059 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Ingmar Bruns — Officer (Chief Medical Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Grant/award | Common Stock | 9,727 | $2 | $21.2K | 43,059 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Grant/award (9,727 shares) |
Keywords
insider transaction, Form 4, ZNTL, Zentalis Pharmaceuticals, Inc., neutral, Ingmar Bruns
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.